对阿尔茨海默病的障碍和解决方案 美国黑人参与临床试验
Jordan Savold1, Michele Cole2, Roland J Thorpe3,4
1Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA.
Alzheimer's & dementia (New York, N. Y.)
|July 6, 2023
概括
美国黑人面临着阿尔茨海默病 (AD) 临床试验参与的重大障碍. 解决健康的社会决定因素和实施行业最佳实践对于改善AD研究的包容性至关重要.
科学领域:
- 神经科学与公共卫生
- 临床试验多样性 临床试验多样性
背景情况:
- 在美国,黑人美国人患阿尔茨海默病 (AD) 的负担不成比例.
- 美国黑人在阿尔茨海默病临床试验中的代表性不足仍然是一个持续的问题.
研究的目的:
- 确定阻碍黑人美国人参与AD临床试验的主要障碍.
- 提供基于文献的建议,以加强对黑人美国人的纳入AD临床试验.
主要方法:
- 在电子数据库和灰色文献中进行了全面的搜索.
- 审查了在美国发表的文章,直到2023年1月1日.
- 26篇关键文章被选中用于综述.
主要成果:
- 参与障碍与健康的社会决定因素有关,包括教育,医疗保健准入,经济稳定,建筑环境和社区环境.
- 提高包容性的有效策略需要制药公司采取多方面的方法.
- 建议的策略包括创新的选址,当地伙伴关系,推广和教育.
结论:
- 解决AD对黑人美国人的不成比例影响需要采取多部门行动.
- 制药行业在通过产品开发和试验管理来提高AD临床试验的多样性方面发挥着至关重要的作用.
相关概念视频
01:22Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220
01:26Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527